

Not to be confused with [Cytokinin](#).

Cytokines (cyto, from [Greek](#) "κύτταρο" *kyttaro* "cell" + *kines*, from [Greek](#) "κίνηση" *kinisi* "movement") are a broad and loose category of small proteins (~5–20 [kDa](#)) that are important in [cell signaling](#). Their release has an effect on the behavior of cells around them. It can be said that cytokines are involved in [autocrine signalling](#), [paracrine signalling](#) and [endocrine signalling](#) as immunomodulating agents. Their definite distinction from hormones is still part of ongoing research. Cytokines include [chemokines](#), [interferons](#), [interleukins](#), [lymphokines](#), and [tumour necrosis factors](#) but generally not [hormones](#) or [growth factors](#) (despite some [overlap in the terminology](#)). Cytokines are produced by a broad range of cells, including immune cells like [macrophages](#), [B lymphocytes](#), [T lymphocytes](#) and [mast cells](#), as well as [endothelial cells](#), [fibroblasts](#), and various [stromal cells](#); a given cytokine may be produced by more than one type of cell.^{[1][2][3]}

They act through [receptors](#), and are especially important in the [immune system](#); cytokines modulate the balance between [humoral](#) and [cell-based](#) immune responses, and they regulate the maturation, growth, and responsiveness of particular cell populations. Some cytokines enhance or inhibit the action of other cytokines in complex ways.^[3]

They are different from hormones, which are also important cell signaling molecules, in that hormones circulate in less variable concentrations and hormones tend to be made by specific kinds of cells.

They are important in health and disease, specifically in host responses to infection, immune responses, [inflammation](#), trauma, [sepsis](#), cancer, and reproduction.

Discovery of cytokines

Interferon-alpha, an [interferon type I](#), was identified in 1957 as a protein that interfered with viral replication.^[4] The activity of interferon-gamma (the sole member of the [interferon type II](#) class) was described in 1965; this was the first identified [lymphocyte](#)-derived mediator.^[4] [Macrophage migration inhibitory factor](#) (MIF) was identified simultaneously in 1966 by John David and Barry Bloom.^[4]

In 1969 Dudley Dumonde proposed the term "lymphokine" to describe proteins secreted from lymphocytes and later, proteins derived from macrophages and monocytes in culture were called "monokines". As scientists learned more, it was understood that these proteins and

others were part of a broader class of proteins involved in self-defense, and should be called "cytokines".^[4]

Difference from hormones

Classic hormones circulate in nanomolar (10^{-9} M) concentrations that usually vary by less than one order of magnitude. In contrast, some cytokines (such as IL-6) circulate in picomolar (10^{-12} M) concentrations that can increase up to 1,000-fold during trauma or infection. The widespread distribution of cellular sources for cytokines may be a feature that differentiates them from hormones. Virtually all nucleated cells, but especially endo/epithelial cells and resident [macrophages](#) (many near the interface with the external environment) are potent producers of [IL-1](#), [IL-6](#), and [TNF- \$\alpha\$](#) .^[5] In contrast, classic hormones, such as insulin, are secreted from discrete glands (e.g., the [pancreas](#)).^[6] As of 2008, the current terminology refers to cytokines as immunomodulating agents. However, more research is needed in this area of defining cytokines and hormones.

Part of the difficulty with distinguishing cytokines from hormones is that some of the immunomodulating effects of cytokines are systemic rather than local. For instance, to use hormone terminology, the action of cytokines may be [autocrine](#) or [paracrine](#) in [chemotaxis](#) or [chemokinesis](#) and [endocrine](#) as a [pyrogen](#). Further, as molecules, cytokines are not limited to their immunomodulatory role.

Nomenclature

Cytokines have been classed as [lymphokines](#), [interleukins](#), and [chemokines](#), based on their presumed function, cell of secretion, or target of action. Because cytokines are characterised by considerable redundancy and [pleiotropism](#), such distinctions, allowing for exceptions, are obsolete.

- The term *interleukin* was initially used by researchers for those cytokines whose presumed targets are principally [leukocytes](#). It is now used largely for designation of newer cytokine molecules and bears little relation to their presumed function. The vast majority of these are produced by [T-helper cells](#).
- *Lymphokines*, produced by lymphocytes

- *Monokines*, produced exclusively by monocytes
- *Interferons*, involved in antiviral responses
- *Colony stimulating factors*, support the growth of cells in semisolid media
- *Chemokines* mediate chemoattraction ([chemotaxis](#)) between cells.

Classification

Structural

Structural homogeneity has been able to partially distinguish between cytokines that do not demonstrate a considerable degree of redundancy so that they can be classified into four types:

- The four-[α-helix bundle](#) family: member cytokines have three-dimensional structures with four bundles of [α-helices](#). This family, in turn, is divided into three sub-families:
 1. the [IL-2](#) subfamily
 2. the [interferon \(IFN\)](#) subfamily
 3. the [IL-10](#) subfamily.
 - The first of these three, the IL-2 subfamily, is the largest. It contains several non-immunological cytokines including [erythropoietin](#) (EPO) and [thrombopoietin](#) (TPO). Furthermore, four-α-helix bundle cytokines can be grouped into *long-chain* and *short-chain* cytokines.
- the [IL-1](#) family, which primarily includes IL-1 and [IL-18](#)
- the [IL-17](#) family, which has yet to be completely characterized, though member cytokines have a specific effect in promoting proliferation of T-cells that cause cytotoxic effects.
- the cysteine-knot cytokines include members of the [transforming growth factor beta superfamily](#), including [TGF-β1](#), [TGF-β2](#) and [TGF-β3](#).

Functional

A classification that proves more useful in clinical and experimental practice outside of [structural biology](#) divides immunological cytokines into those that enhance [cellular immune responses](#), type 1 (TNFα, IFN-γ, etc.), and type 2 (TGF-β, [IL-4](#), [IL-10](#), [IL-13](#), etc.), which favor

[antibody](#) responses.

A key focus of interest has been that cytokines in one of these two sub-sets tend to inhibit the effects of those in the other. Dysregulation of this tendency is under intensive study for its possible role in the [pathogenesis](#) of [autoimmune disorders](#).

Several inflammatory cytokines are induced by [oxidative stress](#).^{[7][8]} The fact that cytokines themselves trigger the release of other cytokines^{[9][10][11]} and also lead to increased oxidative stress makes them important in chronic [inflammation](#), as well as other immunoresponses, such as fever and acute phase proteins of the liver (IL-1,6,12, IFN- α).

Cytokines also play a role in anti-inflammatory pathways and are a possible therapeutic treatment for pathological pain from inflammation or peripheral nerve injury.^[12] There are both pro-inflammatory and anti-inflammatory cytokines that regulate this pathway.

Receptors

Main article: [Cytokine receptor](#)

In recent years, the cytokine receptors have come to demand the attention of more investigators than cytokines themselves, partly because of their remarkable characteristics, and partly because a deficiency of cytokine receptors has now been directly linked to certain debilitating immunodeficiency states. In this regard, and also because the redundancy and pleomorphism of cytokines are, in fact, a consequence of their homologous receptors, many authorities think that a classification of cytokine receptors would be more clinically and experimentally useful.

A classification of cytokine receptors based on their three-dimensional structure has, therefore, been attempted. Such a classification, though seemingly cumbersome, provides several unique perspectives for attractive pharmacotherapeutic targets.

- [Immunoglobulin \(Ig\) superfamily](#), which are ubiquitously present throughout several cells and tissues of the vertebrate body, and share structural [homology](#) with immunoglobulins ([antibodies](#)), [cell adhesion molecules](#), and even some cytokines. Examples: IL-1 receptor types.
- Hemopoietic [Growth Factor](#) (type 1) family, whose members have certain conserved motifs in their extracellular [amino-acid](#) domain. The IL-2 receptor belongs to this chain, whose γ -

chain (common to several other cytokines) deficiency is directly responsible for the x-linked form of [Severe Combined Immunodeficiency \(X-SCID\)](#).

- [Interferon](#) (type 2) family, whose members are receptors for IFN β and γ .
- [Tumor necrosis factors](#) (TNF) (type 3) family, whose members share a [cysteine](#)-rich common extracellular binding domain, and includes several other non-cytokine [ligands](#) like [CD40](#), [CD27](#) and [CD30](#), besides the ligands on which the family is named (TNF).
- [Seven transmembrane helix](#) family, the ubiquitous receptor type of the animal kingdom. All [G protein-coupled receptors](#) (for hormones and neurotransmitters) belong to this family. Chemokine receptors, two of which act as binding proteins for [HIV](#) ([CD4](#) and [CCR5](#)), also belong to this family.
- [Interleukin-17 receptor](#) (IL-17R) family, which shows little homology with any other cytokine receptor family. Structural motifs conserved between members of this family include: an extracellular fibronectin III-like domain, a transmembrane domain and a cytoplasmic SERIF domain. The known members of this family are as follows: IL-17RA, IL-17RB, IL-17RC, IL17RD and IL-17RE.^[13]

Cellular effects

Each cytokine has a matching [cell-surface receptor](#). Subsequent [cascades](#) of intracellular signalling then alter cell functions. This may include the upregulation and/or downregulation of several [genes](#) and their [transcription factors](#), resulting in the production of other cytokines, an increase in the number of surface receptors for other molecules, or the suppression of their own effect by [feedback inhibition](#).

The effect of a particular cytokine on a given cell depends on the cytokine, its extracellular abundance, the presence and abundance of the complementary receptor on the cell surface, and downstream signals activated by receptor binding; these last two factors can vary by cell type. Cytokines are characterized by considerable "redundancy", in that many cytokines appear to share similar functions.

It seems to be a paradox that cytokines binding to [antibodies](#) have a stronger immune effect than the cytokine alone. This may lead to lower therapeutic doses.

Said et al. showed that inflammatory cytokines cause an IL-10-dependent inhibition of^[14] T-cell expansion and function by up-regulating [PD-1](#) levels on monocytes which leads to IL-10

production by monocytes after binding of PD-1 by PD-L.^[14]

Adverse reactions to cytokines are characterized by local inflammation and/or ulceration at the injection sites. Occasionally such reactions are seen with more widespread [papular eruptions](#).^[15]

Roles of endogenous cytokines in health and disease

Cytokines are often involved in several developmental processes during [embryogenesis](#).^{[16][nb 1][17][nb 2]}

Cytokines are crucial for fighting off infections and in other immune responses.^[18] However, they can become dysregulated and pathological in [inflammation](#), trauma, and [sepsis](#).^[18]

Adverse effects of cytokines have been linked to many disease states and conditions ranging from [schizophrenia](#), [major depression](#)^[19] and [Alzheimer's disease](#)^[20] to [cancer](#).^[21] Normal tissue integrity is preserved by feedback interactions between diverse cell types mediated by adhesion molecules and secreted cytokines; disruption of normal feedback mechanisms in cancer threatens tissue integrity.^[22] Over-secretion of cytokines can trigger a dangerous syndrome known as a [cytokine storm](#); this may have been the cause of severe adverse events during a clinical trial of [TGN1412](#). Cytokine storms are suspected to be the main cause of death in the [1918 "Spanish Flu"](#) pandemic. Deaths were weighted more heavily towards people with healthy immune systems, due to its ability to produce stronger immune responses, likely increasing cytokine levels. Another important example of cytokine storm is seen in acute pancreatitis. Cytokines are integral and implicated in all angles of the cascade resulting in the systemic inflammatory response syndrome and multi organ failure associated with this intra-abdominal catastrophe.^[23]

Medical use as drugs

Some cytokines have been developed into [protein therapeutics](#) using [recombinant DNA](#) technology.^[24] Recombinant cytokines being used as drugs as of 2014 include:^[25]

- [Bone morphogenetic protein](#) (BMP), used to treat bone-related conditions
- [Erythropoietin](#) (EPO), used to treat [anemia](#)

- [Granulocyte colony-stimulating factor](#) (G-CSF), used to treat [neutropenia](#) in cancer patients
- [Granulocyte macrophage colony-stimulating factor](#) (GM-CSF), used to treat [neutropenia](#) and [fungal infections](#) in cancer patients
- [Interferon alfa](#), used to treat [hepatitis C](#) and [multiple sclerosis](#)
- [Interferon beta](#), used to treat [multiple sclerosis](#)
- [Interleukin 2](#) (IL-2), used to treat cancer.
- [Interleukin 11](#) (IL-11), used to treat [thrombocytopenia](#) in cancer patients.
- [Interferon gamma](#) is used to treat [chronic granulomatous disease](#)^[26] and [osteopetrosis](#)^[27]

Research into diagnostic use of measured levels

Plasma levels of various cytokines may give information on the presence, or even predictive value of inflammatory processes involved in autoimmune diseases such as [rheumatoid arthritis](#),^[28] as well as immunomodulatory effects of foods or drugs.^[29] In addition, elevated levels of [IL-7](#), an important cytokine involved in T cell homeostasis, have been detected in the plasma of [HIV-infected patients](#).^[30]

See also

- [Active Hexose Correlated Compound](#)
- [Adipokines](#)
- [Apoptosis](#)
- [Cytokine redundancy](#)
- [Cytokine secretion assay](#)
- [Cytokine storm](#)
- [ELISA](#) assays
- [ELISPOT](#) assays
- [FluoroSpot](#) assays
- [Myokine](#)

- [Signal transduction](#)
- [TSLP](#)
- [Virokine](#)

Notes

Wikimedia Commons has media related to [Cytokines](#).

1. [^] Saito explains "much evidence has suggested that cytokines and chemokines play a very important role in the reproduction, i.e. embryo implantation, endometrial development, and trophoblast growth and differentiation by modulating the immune and endocrine systems." (15)
2. [^] Chen explains the regulatory activity of [LIF](#) in human and murine embryos: "In conclusion, human preimplantation embryos express LIF and LIF-R mRNA. The expression of these transcripts indicates that preimplantation embryos may be responsive to LIF originating either from the surrounding environment or from the embryos themselves and exerting its function in a paracrine or autocrine manner."(719)

References

1. [^] "Cytokine" in John Lackie. A Dictionary of Biomedicine. Oxford University Press. 2010. [ISBN 9780199549351](#)
2. [^] "Cytokine" in Stedman's Medical Dictionary, 28th ed. Wolters Kluwer Health, Lippincott, Williams & Wilkins (2006)
3. [^] ^a ^b Horst Ibelgaufts. [Cytokines](#) in Cytokines & Cells Online Pathfinder Encyclopedia Version 31.4 (Spring/Summer 2013 Edition)
4. [^] ^a ^b ^c ^d Alexander G. Izaguirre. [Molecular Mediators, Cytokines I: Lecture I: Topic I: Cytokines](#)
5. [^] Boyle JJ (January 2005). "Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture". *Curr Vasc Pharmacol*. **3** (1): 63–8. [doi:10.2174/1570161052773861](#) . [PMID 15638783](#) .
6. [^] Cannon JG (December 2000). "Inflammatory Cytokines in Nonpathological States". *News Physiol Sci*. **15**: 202–203. [PMID 11200020](#)

7. ^ Vlahopoulos S, Boldogh I, Casola A, Brasier AR; Boldogh; Casola; Brasier (September 1999). "Nuclear factor-kappaB-dependent induction of interleukin-8 gene expression by tumor necrosis factor alpha: evidence for an antioxidant sensitive activating pathway distinct from nuclear translocation". *Blood*. **94** (6): 1878–89. PMID 10477716 .
8. ^ David F, Farley J, Huang H, Lavoie JP, Lavery S; Farley; Huang; Lavoie; Lavery (April 2007). "Cytokine and chemokine gene expression of IL-1beta stimulated equine articular chondrocytes". *Vet Surg*. **36** (3): 221–7. doi:10.1111/j.1532-950X.2007.00253.x . PMID 17461946 .
9. ^ Chokkalingam, V.; Tel, J.; Wimmers, F.; Liu, X.; Semenov, S.; Thiele, J.; Figdor, C. G.; Huck, W. T. S. (2013). "Probing cellular heterogeneity in cytokine-secreting immune cells using droplet-based microfluidics". *Lab on a Chip*. **13** (24): 4740–4744. doi:10.1039/C3LC50945A . PMID 24185478 .
10. ^ Carpenter LR, Moy JN, Roebuck KA; Moy; Roebuck (March 2002). "Respiratory syncytial virus and TNF alpha induction of chemokine gene expression involves differential activation of Rel A and NF-kappa B1" . *BMC Infect. Dis.* **2**: 5. doi:10.1186/1471-2334-2-5 . PMC 102322 . PMID 11922866 .
11. ^ Tian B, Nowak DE, Brasier AR; Nowak; Brasier (2005). "A TNF-induced gene expression program under oscillatory NF-kappaB control" . *BMC Genomics*. **6**: 137. doi:10.1186/1471-2164-6-137 . PMC 1262712 . PMID 16191192 .
12. ^ Zhang, Jun-Ming; An, Jianxiong (2007-01-01). "Cytokines, Inflammation and Pain" . *International anesthesiology clinics*. **45** (2): 27–37. doi:10.1097/AIA.0b013e318034194e . ISSN 0020-5907 . PMC 2785020 . PMID 17426506 .
13. ^ Gaffen SL (August 2009). "Structure and signalling in the IL-17 receptor family" . *Nat. Rev. Immunol.* **9** (8): 556–67. doi:10.1038/nri2586 . PMC 2821718 . PMID 19575028 .
14. ^ ^{a b} Said EA, Dupuy FP, Trautmann L, et al. (April 2010). "Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection" . *Nat. Med.* **16** (4): 452–9. doi:10.1038/nm.2106 . PMC 4229134 . PMID 20208540 .
15. ^ James, William; Berger, Timothy; Elston, Dirk (2005). *Andrews' Diseases of the Skin: Clinical Dermatology*. (10th ed.). Saunders. ISBN 0-7216-2921-0.
16. ^ Saito S (2001). "Cytokine cross-talk between mother and the embryo/placenta". *J.*

Reprod. Immunol. **52** (1–2): 15–33. doi:[10.1016/S0165-0378\(01\)00112-7](https://doi.org/10.1016/S0165-0378(01)00112-7) .
PMID [11600175](https://pubmed.ncbi.nlm.nih.gov/11600175/) .

17. [^] Chen HF, Shew JY, Ho HN, Hsu WL, Yang YS; Shew; Ho; Hsu; Yang (October 1999). "Expression of leukemia inhibitory factor and its receptor in preimplantation embryos". *Fertil. Steril.* **72** (4): 713–9. doi:[10.1016/S0015-0282\(99\)00306-4](https://doi.org/10.1016/S0015-0282(99)00306-4) . PMID [10521116](https://pubmed.ncbi.nlm.nih.gov/10521116/) .

18. [^] ^a ^b Dinarello CA (August 2000). "Proinflammatory cytokines". *Chest.* **118** (2): 503–8. doi:[10.1378/chest.118.2.503](https://doi.org/10.1378/chest.118.2.503) . PMID [10936147](https://pubmed.ncbi.nlm.nih.gov/10936147/) .

19. [^] Dowlati Y, Herrmann N, Swardfager W, et al. (March 2010). "A meta-analysis of cytokines in major depression". *Biol. Psychiatry.* **67** (5): 446–57. doi:[10.1016/j.biopsych.2009.09.033](https://doi.org/10.1016/j.biopsych.2009.09.033) . PMID [20015486](https://pubmed.ncbi.nlm.nih.gov/20015486/) .

20. [^] Swardfager W, Lanctôt K, Rothenburg L, Wong A, Cappell J, Herrmann N; Lanctôt; Rothenburg; Wong; Cappell; Herrmann (November 2010). "A meta-analysis of cytokines in Alzheimer's disease". *Biol. Psychiatry.* **68** (10): 930–41. doi:[10.1016/j.biopsych.2010.06.012](https://doi.org/10.1016/j.biopsych.2010.06.012) . PMID [20692646](https://pubmed.ncbi.nlm.nih.gov/20692646/) .

21. [^] Locksley RM, Killeen N, Lenardo MJ; Killeen; Lenardo (February 2001). "The TNF and TNF receptor superfamilies: integrating mammalian biology". *Cell.* **104** (4): 487–501. doi:[10.1016/S0092-8674\(01\)00237-9](https://doi.org/10.1016/S0092-8674(01)00237-9) . PMID [11239407](https://pubmed.ncbi.nlm.nih.gov/11239407/) .

22. [^] Vlahopoulos, SA; Cen, O; Hengen, N; Agan, J; Moschovi, M; Critselis, E; Adamaki, M; Bacopoulou, F; Copland, JA; Boldogh, I; Karin, M; Chrousos, GP (20 June 2015). "Dynamic aberrant NF-κB spurs tumorigenesis: A new model encompassing the microenvironment.". *Cytokine & Growth Factor Reviews.* **26**: 389–403. doi:[10.1016/j.cytogfr.2015.06.001](https://doi.org/10.1016/j.cytogfr.2015.06.001) .
PMID [26119834](https://pubmed.ncbi.nlm.nih.gov/26119834/) .

23. [^] Makhija R, Kingsnorth AN; Kingsnorth (2002). "Cytokine storm in acute pancreatitis". *J Hepatobiliary Pancreat Surg.* **9** (4): 401–10. doi:[10.1007/s005340200049](https://doi.org/10.1007/s005340200049) .
PMID [12483260](https://pubmed.ncbi.nlm.nih.gov/12483260/) .

24. [^] Horst Ibelgaufts. [Recombinant cytokines](#) in Cytokines & Cells Online Pathfinder Encyclopedia Version 31.4 (Spring/Summer 2013 Edition)

25. [^] Dimiter S. Dimitrov. [Therapeutic Proteins](#) .Chapter 1 in Therapeutic Proteins: Methods and Protocols, Editors: Vladimir Voynov, Justin A. Caravella. Volume 899 of Methods in Molecular Biology. Springer Science+Business Media, LLC 2012. ISBN [978-1-61779-920-4](https://doi.org/10.1007/978-1-61779-920-4) (Print) [978-1-61779-921-1](https://doi.org/10.1007/978-1-61779-921-1) (Online)

26. [^] ^a ^b Dinarello CA (August 2000). "Proinflammatory cytokines". *Chest.* **118** (2): 503–8. doi:[10.1378/chest.118.2.503](https://doi.org/10.1378/chest.118.2.503) . PMID [10936147](https://pubmed.ncbi.nlm.nih.gov/10936147/) .

26. ^ Woodman, RC; Erickson, RW; Rae, J; Jaffe, HS; Curnutte, JI (Mar 15, 1992). "Prolonged recombinant interferon-gamma therapy in chronic granulomatous disease: evidence against enhanced neutrophil oxidase activity.". *Blood*. **79** (6): 1558–62. [PMID 1312372](#) .
27. ^ Key LL, Jr; Rodriguiz, RM; Willi, SM; Wright, NM; Hatcher, HC; Eyre, DR; Cure, JK; Griffin, PP; Ries, WL (Jun 15, 1995). "Long-term treatment of osteopetrosis with recombinant human interferon gamma". *The New England Journal of Medicine*. **332** (24): 1594–9. [doi:10.1056/NEJM199506153322402](#) . [PMID 7753137](#) .
28. ^ Kokkonen, H. Arthritis & Rheumatism, Feb. 2, 2010; vol 62: pp 383–391
29. ^ Nikolaeva LG, Maystat TV, Masyuk LA, Pylypchuk VS, Volyanskii YL, Kutsyna GA; Maystat; Masyuk; Pylypchuk; Volyanskii; Kutsyna (2009). "[Changes in CD4+ T-cells and HIV RNA resulting from combination of anti-TB therapy with Dzherele in TB/HIV dually infected patients](#)" . *Drug Des Devel Ther*. **2**: 87–93. [PMC 2761183](#) . [PMID 19920896](#) .
30. ^ Napolitano LA, Grant RM, Deeks SG, et al. (January 2001). "Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis". *Nat. Med*. **7** (1): 73–9. [doi:10.1038/83381](#) . [PMID 11135619](#) .

External links

- [Cytokine Signalling Forum](#)
- [Cytokine Gene Summary, Ontology, Pathways and More: Immunology Database and Analysis Portal \(ImmPort\)](#)
- [Cytokine Tutorial](#) . dead link.
- [Cell Interactions: Cytokines](#) . inactive link
- [Reperfusion Injury in Stroke](#) .
- [CopeWithCytoKines Cytokines Online Pathfinder Encyclopaedia](#)